Full Press Release Details
• First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes
• Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers
• Designed for compatibility with leading automated insulin delivery (AID) systems
ABBOTT PARK, Ill. , May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT ), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing real-time visibility into both glucose levels needed for daily diabetes management as well as rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency. This marks the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests. Abbott plans to begin launching Libre Duo systems in select European countries later this year.